Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thoracic Neoplasms 1Small Cell Lung Carcinoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Breast Neoplasms 1

Interventions

Gemcitabine 11pembrolizumab 10Oxaliplatin 7Nivolumab 7Irinotecan 7Fluorouracil 7Capecitabine 7durvalumab 6Sorafenib 6Leucovorin 6Cyclophosphamide 6Paclitaxel 5Ipilimumab 5tislelizumab 3poly ICLC 3lenvatinib 3fludarabine 3Sunitinib 3Radiotherapy 3Cisplatin 3Cetuximab 3130-nm albumin-bound paclitaxel 3seocalcitol 2selinexor 2pemigatinib 2futuximab 2fludarabine phosphate 2donafenib 2cemiplimab 2atezolizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma × efineptakin alfa × Gastrointestinal × Clear all
NCT04332653 2026-03-09

NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

NeoImmuneTech

Phase 1/2 Completed
215 enrolled 30 charts
BreastGastrointestinalGynecologicThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Thoracic Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡